1. DOP88 Long-term real-world data of ustekinumab in Crohn's Disease – the Stockholm ustekinumab study – STOCUSTE. (21st January 2022) Authors: Bello, F; Lördal, M; Johansson, F; Sabhan, H; Muhsen, S; Borin, A; Forsberg, O; Wennerström, C; Söderman, C; Almer, S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P758 Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn's disease (SVEAH CD). (16th January 2018) Authors: Eriksson, C; Rundquist, S; Lykiardopoulos, V; Karlén, P; Grip, O; Söderman, C; Almer, S; Hertervig, E; Gunnarsson, J; Malmgren, C; Delin, J; Strid, H; Sjöberg, M; Öberg, D; Bergemalm, D; Udumyan, R; Hjortswang, H; Halfvarson, J Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S494 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗